Multivariate logistic analysis grouped by type of therapy
| Rapid viral response | Lead-in | Undetectable or VL ≤15 UI | ||||
|---|---|---|---|---|---|---|
| Type of therapy | OR | 95% CI | p Value | OR | 95% CI | p Value |
| Treatment initiation (Season A vs Season B | 43.31 | 1.88 to 996.65 | 0.019 | 3.36 | 1.10 to 10.16 | 0.031 |
| HCV RNA (≤600 000 vs >600 000 IU/mL) | 23.95 | 2.75 to 208.41 | 0.004 | 8.86 | 3.02 to 25.94 | <0.001 |
| IL-28 polymorphism (CC vs no CC) | 7.29 | 0.94 to 56.17 | 0.056 | 4.00 | 1.34 to 11.94 | 0.013 |
| Naïve vs experienced | 5.68 | 0.591 to 54.56 | 0.132 | 1.02 | 0.37 to 2.86 | 0.959 |
| Genotype (1b vs 1a) | 0.18 | 0.02 to 1.62 | 0.128 | 0.55 | 0.17 to 1.799 | 0.328 |
| Diabetes mellitus (no vs yes) | 0.27 | 0.02 to 3.62 | 0.326 | 0.98 | 0.19 to 0.87 | 0.985 |
| Age (≥50 vs <50 years) | 2.78 | 0.44 to 17.65 | 0.276 | 1.38 | 0.48 to 3.97 | 0.542 |
| Fibrosis (≥F3 vs <F3) | 3.69 | 0.22 to 62.58 | 0.365 | 0.98 | 0.17 to 5.63 | 0.987 |
| Rapid viral response | Without lead-in | Undetectable or VL ≤15 UI | ||||
| Type of therapy | OR | 95% CI | p Value | OR | 95% CI | p Value |
| Treatment initiation (Season A vs Season B | 1.78 | 1.93 to 2.90 | 0.021 | 1.61 | 0.86 to 3.01 | 0.131 |
| HCV RNA (≤600 000 vs >600 000 IU/mL) | 1.76 | 1.04 to 3.00 | 0.035 | 3.11 | 1.32 to 7.30 | 0.009 |
| IL-28 polymorphism (CC vs no CC) | 1.81 | 1.03 to 3.16 | 0.037 | 1.84 | 0.83 to 4.08 | 0.132 |
| Naïve vs experienced | 1.51 | 0.87 to 2.63 | 0.138 | 0.66 | 0.32 to 1.36 | 0.267 |
| Genotype (1b vs 1a) | 1.52 | 0.81 to 2.84 | 0.191 | 0.74 | 0.33 to 1.64 | 0.468 |
| Diabetes mellitus (no vs yes) | 1.36 | 0.64 to 2.85 | 0.416 | 1.57 | 0.67 to 3.67 | 0.296 |
| Age (≥50 vs <50 years) | 0.83 | 0.49 to 1.40 | 0.488 | 0.87 | 0.44 to 1.69 | 0.684 |
| Fibrosis (≥F3 vs <F3) | 0.88 | 0.48 to 1.60 | 0.681 | 1.89 | 0.82 to 4.38 | 0.133 |